StockWatch
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Quarterly ResultMay 14, 2026, 04:42 PM

CapsoVision Q1 Net Loss $(7.03)M; Going Concern Doubt Raised

AI Summary

CapsoVision reported a net loss of $7.03 million for the first quarter of 2026, an increase from $5.38 million in the prior year, while net revenue remained relatively flat at $2.79 million. The company successfully raised approximately $14 million in gross proceeds through a private placement of common stock in March 2026. Despite this capital infusion, management expressed substantial doubt about the company's ability to continue as a going concern for the next year, citing ongoing operating losses and negative cash flows.

Key Highlights

  • Net loss for Q1 2026 was $(7.03) million, up from $(5.38) million in Q1 2025.
  • Net revenue for Q1 2026 was $2.79 million, slightly up from $2.78 million in Q1 2025.
  • Research and development expenses increased to $4.44 million in Q1 2026 from $3.11 million.
  • Company raised $14 million gross proceeds from a private placement in March 2026.
  • Cash and cash equivalents increased to $17.93 million as of March 31, 2026.
  • Management raised substantial doubt about the company's ability to continue as a going concern.
  • Net cash used in operating activities was $(6.07) million in Q1 2026.
  • Total stockholders' equity increased to $20.22 million from $13.26 million.